Eaton, Keith

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 7,945

Plasma processing conditions substantially influence circulating microRNA biomarker levels

Cheng, H. H., Yi, H. S., Kim, Y., Kroh, E. M., Chien, J. W., Eaton, K. D., Goodman, M. T., Tait, J. F., Tewari, M., & Pritchard, C. C. (2013) · PLoS ONE

MicroRNA in disease regulationExtracellular vesicles in disease

Cited by 317

A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer

Giaccone, G., Bazhenova, L. A., Nemunaitis, J., Tan, M., Juhász, E., Ramlau, R., van den Heuvel, M. M., Lal, R., Kloecker, G. H., Eaton, K. D., et al. (2015) · European Journal of Cancer

Lung Cancer Diagnosis and TreatmentLung Cancer Research Studies

Cited by 279